-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653.P1.38 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 11, 2021: 5:30 PM-7:30 PM
Hall B5, Level 1, Building B (Georgia World Congress Center)

Malin Hultcrantz, MD PhD1, David Kleinman, MD2*, Pavandeep Ghataorhe, MD, PhD3*, Astrid McKeown, PhD3*, Wei He, PhD4*, Thomas Ling, BSc3*, Roxanne C Jewell, PhD5*, Joseph Brunner, MS6*, Julie Byrne, PhD6*, Laurie Eliason6*, Emma Scott, MD6* and Joanna Opalinska, MD6

1Memorial Sloan Kettering Cancer Center, New York, NY
2University of Rochester, Rochester, NY
3GlaxoSmithKline, London, United Kingdom
4GlaxoSmithKline, Cambridge, MA
5GlaxoSmithKline, Research Triangle Park, NC
6GlaxoSmithKline, Upper Providence, PA

Saad Z. Usmani, MD MBA FACP1, Shaji K Kumar, MD2, Torben Plesner, MD3, Robert Z. Orlowski4, Philippe Moreau, MD, PhD5*, Nizar J. Bahlis, MD6, Supratik Basu7*, Hareth Nahi8*, Cyrille Hulin9*, Hang Quach, FRACP, FRCPA10, Hartmut Goldschmidt11, Michael E. O'Dwyer, MD12, Aurore Perrot13*, Chris P. Venner14, Katja Weisel15*, Joseph R. Mace16*, Noopur S. Raje, MD17, Mourad Tiab18*, Margaret Macro19*, Laurent Frenzel20*, Xavier Leleu, MD21, Huiling Pei, PhD22*, Rian Van Rampelbergh23*, Brenda Tromp24, Maria Delioukina25* and Thierry Facon26*

1Levine Cancer Institute, New York, NY
2Department of Hematology, Mayo Clinic Rochester, Rochester, MN
3Vejle Hospital and University of Southern Denmark, Vejle, Denmark
4Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
5Hematology, University Hospital Hôtel-Dieu, Nantes, France
6Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
7The Royal Wolverhampton Hospitals NHS Trust and University of Wolverhampton, Wolverhampton, United Kingdom
8Karolinska University Hospital at Huddinge, Karolinska Institute, Stockholm, Sweden
9Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France
10University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC, Australia
11University Hospital Heidelberg, Heidelberg, Germany
12Department of Medicine/Haematology, NUI, Galway, Ireland
13CHU de Toulouse, IUCT-O, Université de Toulouse, Toulouse, France
14University of Alberta, Edmonton, AB, Canada
15Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
16Florida Cancer Specialists, St. Petersburg, FL
17Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA
18CHD Vendée, La Roche sur Yon, France
19Centre Hospitalier Universitaire (CHU) de Caen, Caen, France
20Department of Clinical Haematology, Hopital Necker-Enfants Malades, Paris, France
21CHU Poitiers, Hôpital la Milétrie, Poitiers, France
22Janssen Research & Development, LLC, Titusville, NJ
23Janssen Research & Development, Beerse, Belgium
24Janssen Research & Development, Leiden, Netherlands
25Janssen Research & Development, LLC, Spring House, PA
26University of Lille, CHU Lille, Lille, France

Paula Rodriguez-Otero1*, Bhagirathbhai Dholaria, MBBS2, Elham Askari3*, Donna E. Reece4, Niels W.C.J. van de Donk5, Ajai Chari, MD6*, Hartmut Goldschmidt7, Amrita Y. Krishnan, MD8, Thomas Martin, MD9, Maria-Victoria Mateos10, Daniel Morillo Giles3*, Cesar Rodriguez11, Laura Rosinol12*, Jesús F. San-Miguel1, Anna Sureda13, Ralph Wäsch14, Katja Weisel15*, Raluca I. Verona16*, Shun Xin Wang Lin16*, Thomas J. Prior16*, Brendan M. Weiss16, Mark Wade16*, Jenna D. Goldberg17*, Albert Oriol18* and Parameswaran Hari19

1Clinica Universidad de Navarra, Navarra, Spain
2Vanderbilt University Medical Center, Nashville, TN
3Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
4Princess Margaret Cancer Centre, Toronto, ON, Canada
5Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
6Mount Sinai School of Medicine, New York, NY
7University Hospital Heidelberg and National Center of Tumor Diseases, Heidelberg, Germany
8City of Hope Comprehensive Cancer Center, Duarte, CA
9University of California San Francisco, San Francisco, CA
10University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
11Wake Forest University School of Medicine, Winston-Salem, NC
12Institute of Hematology and Oncology, Hematology Department, IDIBAPS Hospital Clínic University of Barcelona, Barcelona, Spain
13Institut Català d'Oncologia – Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
14Freiburg University Medical Center, Frieburg, Germany
15University Medical Center Hamburg-Eppendorf, Hamburg, Germany
16Janssen Research & Development, Spring House, PA
17Janssen Research & Development, Raritan, NJ
18Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
19Medical College of Wisconsin, Milwaukee, WI

Jianxiang Wang, MD1, Weijun Fu, PhD2*, Soo-Mee Bang, MD, PhD3, Honghui Huang, PhD, MD4*, Kihyun Kim5*, Wei Li, MD6*, Gang An, MD, PhD1*, Je-Jung Lee, MD, PhD7, Zhen Cai8*, Jie Jin, MD8, Yafei Wang9*, CS Chim, MD, PhD, BMBS10, Paula Rodriguez-Otero11*, Anna Marina Liberati, MD12, Hiroyuki Takamatsu, MD, PhD13, Jae Hoon Lee, MD, PhD14, Meletios A. Dimopoulos, MD15, Susan Wroblewski, PhD16*, Robin Carson, MD, BA16, Ming Qi, MD, PhD16, Jianping Wang17*, Yang Song18*, Bin Jia19*, Xue Yang19*, Wenyu Liu18*, Yunan Li20*, Renyi Zhang21* and Jian Hou4*

1Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2Shanghai Changzheng Hospital, Shanghai, China
3Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South)
4Department of Hematology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
5Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
6Department of Hematology at the Oncology Center, The First Hospital of Jilin University, Changchun, China
7Department of Hematology-Oncology, Chonnam National University Medical School, Hwasun, Jeollanamdo, Korea, Republic of (South)
8The First Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, Zhejiang, China
9Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
10Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong
11Clínica Universidad de Navarra, Pamplona, Spain
12Azienda Ospedaliera "Santa Maria", Terni, Italy
13Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan
14Gachon University Gil Medical Center, Incheon, Korea, Republic of (South)
15National and Kapodistrian University of Athens, Athens, Greece
16Janssen Research & Development, LLC, Spring House, PA
17Janssen Research & Development, LLC, Raritan, NJ
18Janssen Research & Development, LLC, Beijing, China
19Janssen Research & Development, LLC, Shanghai, China
20Medical Affairs, Xian Janssen Pharmaceutical Ltd., Beijing, China
21Medical Affairs, Xian Janssen Pharmaceutical Ltd., Shanghai, China

Omar Nadeem, MD1, Robert A. Redd, MS2*, Michael Z. Koontz, MD3, Jeffrey V. Matous, MD4, Andrew J. Yee, MD5, Jeffrey A. Zonder, MD 6, Andrew Kin, MD7, Jacalyn Rosenblatt, MD8, Julia Prescott, MSN, NP9*, Kelsey Tague10*, Veronica Romines10*, Meredith Bertoni10*, Amada Metivier10*, Rebekah Medina10*, Alexandra Savell, BS9*, Houry Leblebjian, PharmD, BCOP11*, Alexandra Distaso12*, Clifton C Mo, MD12*, Jacob P. Laubach, MD13, Adam S. Sperling, MD, PhD14, Paul G. Richardson, MD15 and Irene M. Ghobrial, MD16

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
3Pacific Cancer Care, Morgan Hill, CA
4Sarah Cannon Research Institute, Colorado Blood Cancer Institute, Denver, CO
5Massachusetts General Hospital Cancer Center, Boston, MA
6Karmanos Cancer Institute, Detroit, MI
7Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/ Wayne State University, Detroit, MI
8Beth Israel Deaconess Medical Center, Boston, MA
9Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
10Dana-Farber Cancer Institute, Boston
11Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA
12Dana-Farber Cancer Institute, Boston, MA
13The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Newton, MA
14Division of Hematology, Dana-Farber Cancer Institute, Boston, MA
15Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
16Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Omar Nadeem, MD1,2, Robert A. Redd, MS3*, Peter Barth, MD4, Clifton C Mo, MD5*, Jacob P. Laubach, MD6, Giada Bianchi, MD7, Trevor J. Bayliss, MD8*, Vaishali Sanchorawala, MD9, Leyla Shune, MD10, Alexandra Distaso5*, Virginia Dalton, MS, APRN11*, Mary McKenney, NP11*, Sarah Patches12*, Isabella Hou5*, Lindsay Issokson13*, Anna Barrell13*, Kelly Masone, BA5*, Adam S. Sperling, MD, PhD14, Nikhil C. Munshi, MD, PhD15, Irene M. Ghobrial, MD2,16, Kenneth C. Anderson, MD17 and Paul G. Richardson, MD18

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Harvard Medical School, Boston, MA
3Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
4Department of Medicine, Alpert Medical School of Brown University, Providence, RI
5Dana-Farber Cancer Institute, Boston, MA
6The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Newton, MA
7Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA
8Berkshire Health Services, Pittsfield, MA
9Amyloidosis Center, Boston Medical Center Corporation, Boston, MA
10Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
11The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
12Dana Farber Cancer Insititute, Boston, MA
13Dana-Farber Cancer Institute, Boston
14Division of Hematology, Dana-Farber Cancer Institute, Boston, MA
15Dana-Farber Cancer Institute, Harvard Medical School, Boston
16Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
17Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
18Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA

Suzanne Lentzsch, MD, PhD1*, Brea Lipe, MD2, Sascha A. Tuchman, MD3, Nizar J. Bahlis, MD4, William I. Bensinger, MD5*, Michael Sebag, MD, PhD6, Heather J. Sutherland, MD, PhD, FRCPC7, Jorge Monge, MD8*, Cristina J. Gasparetto, MD9*, Muhamed Baljevic, MD10, Natalie S. Callander, MD11, Christopher P. Venner, MD12*, Darrell J. White, MD13, Rami Kotb, MD14, Christine I. Chen, MD15, Gary J. Schiller, MD16, Sumit Madan, MD17*, Richard Leblanc, MD, FRCPC18, Andrew DeCastro, PhD19*, Ohad S. Bentur, MD MHA19*, Jatin J. Shah, MD19*, Dane R. Van Domelen, PhD19*, Michael G. Kauffman, MD, PhD19, Sharon Shacham, PhD, MBA19* and Noa Biran, MD20

1Multiple Myeloma and Amyloidosis Service, Columbia University Medical Center, New York, NY
2Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
3Department of Medicine, Division of Hematology, University of North Carolina, Durham, NC
4Southern Alberta Cancer Research Institute, Calgary, AB, Canada
5Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
6Division of Hematology, McGill University Health Centre, Montreal, QC, Canada
7Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada
8Weill Cornell Medicine, New York, NY
9Duke University Medical Center, Durham, NC
10University of Nebraska Medical Center, Omaha, NE
11Carbone Cancer Center, University of Wisconsin, Madison, WI
12Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
13Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada
14Medical Oncology and Hematology, Cancer Care Manitoba, Winnipeg, MB, Canada
15Department of M, Princess Margaret Cancer Centre, Toronto, ON, Canada
16University of California Los Angeles, Los Angeles, CA
17Banner MD Anderson Cancer Center, Gilbert, AZ
18Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada
19Karyopharm Therapeutics Inc., Newton, MA
20John Theurer Cancer Center, Hackensack Meridian Health, Hackensack University Medical Center, Hackensack, NJ

Sikander Ailawadhi, MD1, Patrick Stiff, MD2, Emad Ibrahim, MBBCh, MD3, Damian J. Green, MD4, Brea Lipe, MD5, Elizabeth H. Cull, MD6, Natalie S. Callander, MD7, John Friend, MD8, Jarrod Longcor8* and Kate Oliver, BS8*

1Division of hematology, Mayo Clinic, Jacksonville, FL
2Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL
3Redlands Community Hospital, Redlands, CA
4Fred Hutchinson Cancer Research Center, Seattle, WA
5Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
6Cancer Institute, Prisma Health, Piedmont, SC
7University of Wisconsin, Madison, WI
8Cellectar Biosciences, Florham Park, NJ

Suzanne Trudel, MD1, Arleigh McCurdy, MD, MPH2, Heather J. Sutherland, MD, PhD, FRCPC3, Martha L Louzada, MD, MSc4, Christopher P. Venner, MD5*, Hira S Mian, MD6, Rami Kotb, MD7, Ibraheem Othman, MD, MSc, PhD8, Fernando Camacho, PhD9*, Engin Gul, BSc, MBA10*, Donna E. Reece11, Darrell J White, MD12 and Molei Fu, MSc9*

1Princess Margaret Cancer Centre, Toronto, ON, Canada
2Department of Medicine, Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada
3Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada
4University of Western Ontario, London Health Sciences Centre, London, ON, Canada
5Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
6Juravinski Cancer Centre (Hamilton-CCO), Hamilton, ON, Canada
7CancerCare Manitoba, Winnipeg, MB, Canada
8Allan Blair Cancer Centre, Regina, SK, CAN
9Canadian Myeloma Research Group (formerly MCRN), Vaughan, ON, Canada
10Canadian Myeloma Research Group (CMRG), Toronto, ON, Canada
11Canadian Myeloma Research Group (formerly MCRN), Toronto, Canada
12Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

Sumit Madan, MD1*, Al-Ola Abdallah, MD2, Andrew J. Cowan, MD3, William I. Bensinger, MD4,5*, Jens Hillengass6, Xavier Leleu, MD7, Eva Medvedova, MD8*, Caitlin Costello, MD9, Brea Lipe, MD10, Henning Schade, MD11*, Rajneesh Nath, MD12* and Liping Laura Sun, PhD12*

1Banner MD Anderson Cancer Center, Gilbert, AZ
2Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
3University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
4Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
5Fred Hutchinson Cancer Rsch. Ctr., Seattle, WA
6Roswell Park Comprehensive Cancer Center, Buffalo, NY
7Department of Hematology, CHU Poitiers – Hôpital la Milétrie, Poitiers, France
8Oregon Health & Science University, Portland, OR
9UC San Diego Health, Moores Cancer Center, La Jolla, CA
10Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
11Colorado Blood Cancer Institute, Denver, CO
12Harpoon Therapeutics, South San Francisco, CA

Aurore Perrot, MD, PhD1*, Thierry Facon2*, Shaji K Kumar, MD3, Torben Plesner, MD4, Robert Z. Orlowski5, Philippe Moreau, MD, PhD6*, Nizar J. Bahlis, MD7, Supratik Basu8*, Hareth Nahi9*, Cyrille Hulin10*, Hang Quach, FRACP, FRCPA11, Hartmut Goldschmidt12, Michael E. O'Dwyer, MD13, Chris P. Venner14, Katja Weisel15*, Joseph R. Mace16*, Noopur S. Raje, MD17, Mourad Tiab18*, Magaret Macro19*, Laurent Frenzel, MD, PhD20, Xavier Leleu, MD21, Kevin Liu22*, John Fastenau23*, Katharine S. Gries23*, Kai Fai Ho24*, Pankaj Mistry25*, Brenda Tromp26, Maria Delioukina27*, Jessica Vermeulen26 and Saad Z. Usmani, MD MBA FACP28

1CHU de Toulouse, IUCT-O, Université de Toulouse, Toulouse, France
2University of Lille, CHU Lille, Lille, France
3Mayo Clinic, Rochester, MN
4Vejle Hospital, Vejle, Denmark
5The University of Texas MD Anderson Cancer Center, Houston, TX
6University Hospital Hôtel-Dieu, Nantes, Nantes, France
7Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
8The Royal Wolverhampton NHS Trust and University of Wolverhampton, Wolverhampton, United Kingdom
9Karolinska University Hospital at Huddinge, Karolinska Institute, Stockholm, Sweden
10Hôpital Haut Leveque, University Hospital, Pessac, France
11St. Vincent’s Hospital, Melbourne, VIC, Australia
12University Hospital Heidelberg and National Center of Tumor Diseases, Heidelberg, Germany
13National University of Ireland, Galway, Ireland
14University of Alberta, Edmonton, AB, Canada
15University Medical Center Hamburg-Eppendorf, Hamburg, Germany
16Florida Cancer Specialists & Research Institute, St. Petersburg, FL
17Massachusetts General Hospital Cancer Center, Boston, MA
18Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France
19Haematology Department, Caen University Hospital, Caen, France
20Assistance Publique–Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
21Service D'Hématologie Et Thérapie Cellulaire, Poitiers, France
22Janssen Global Services, Raritan, NJ
23Janssen Research & Development, Raritan, NJ
24STAT-TU, Inc, Toronto, ON, Canada
25Janssen Research & Development, High Wycombe, United Kingdom
26Janssen Research & Development, Leiden, Netherlands
27Janssen Research & Development, LLC, Spring House, PA
28Levine Cancer Institute/Atrium Health, Charlotte, NC

Meletios A. Dimopoulos, MD1, S. Vincent Rajkumar, MD2*, Sagar Lonial, MD, FACP3, Wee-Joo Chng4, Shinsuke Iida, MD, PhD5, Maria-Victoria Mateos6, Gareth J. Morgan, MD, PhD7, Arun Kumar8*, Kaveri Suryanarayan, MD8*, Alexander Vorog, MD9*, Andrew Fergus8* and Richard Labotka, MD8

1National and Kapodistrian University of Athens, Athens, Greece
2Division of Hematology, Mayo Clinic, Rochester, MN
3Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University Medical School, Emory University, Atlanta, GA
4Department of Hematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore
5Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
6University Hospital of Salamanca, CIC, IBMCC, Salamanca, Spain
7Perlmutter Cancer Center, NYU Langone Health, New York, NY
8Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
9Takeda Development Center Americas, Inc., Lexington, MA

Meral Beksac, MD1, Tulin Tuglular, MD2*, Ali Unal, MD3, Michele Cavo, MD, PhD4*, Francesca Gay, MD, PhD5, Eirini Katodritou, MD6*, Guner Hayri Ozsan, MD7*, Guldane Cengiz, MD1*, Omur Gokmen Sevindik, MD1, Serena Merante, MD8*, Kyriaki Manousou, MSc9*, Pieter Sonneveld10 and Evangelos Terpos, MD, PhD11

1Department of Hematology, Ankara University Faculty Of Medicine Cebeci Hospital, Ankara, Turkey
2Department of Internal Medicine, Marmara University, Istanbul, Turkey
3Department of Hematology, Faculty of Medicine, Erciyes University, Melikgazi, Kayseri, Turkey
4Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
5University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
6Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece
7Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Dokuz Eylul University, Izmir, Turkey
8European Myeloma Network, Pavia, Italy
9Health Data Specialists, Dublin, Ireland
10Erasmus University Medical Center, Rotterdam, Netherlands
11Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Stefania Stefania Mancia1*, Annamaria Farrell, PhD2,3*, Karen Louw, NP2*, Erika Florendo, NP4*, Elizabeth Aronson, NP2*, Kiah Purcell, NP2*, Donna D Catamero, ANP-BC, OCN, CCRC5*, Juliet Escalon, NP2*, Joanne Thomas, PhD, RN6*, Annel Aponte, RN2*, Angela Lamb, MD2*, Diana Kirke, MD2*, Aimee Lucas, MD2*, Sundar Jagannath7, Hearn Jay Cho, MD, PhD8, Samir Parekh, MD8, Joshua Richter, MD9, Larysa Sanchez, MD10 and Ajai Chari, MD11

1The Mount Sinai Hospital, New York, NY
2Mount Sinai Hospital, New York, NY
3Regeneron, Terrytown, NY
4Tisch Cancer Institute, Mt. Sinai School of Medicine, New York, NY
5The Mount Sinai Medical Center, New York, NY
6Icahn School of Medicine At Mount Sinai, New York, NY
7Department of Medicine, Hematology and Medical Oncology, Mount Sinai Medical Center, New York, NY
8Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
9Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
10Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
11Department of Hematology and Medical Oncology, Tisch Cancer Institute, Mt. Sinai School of Medicine, New York, NY

Catherine R. Marinac, PhD1, Robert A. Redd, MS2*, Julia Prescott, MSN, NP3*, Alexandra Savell, BS3*, Courtney Igne4*, Jacob P. Laubach, MD5, Adam S. Sperling, MD, PhD6, Aric D. Parnes, MD7, Houry Leblebjian, PharmD, BCOP8*, Paul G. Richardson, MD9, Irene M. Ghobrial, MD1,10 and Omar Nadeem, MD11

1The Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA
2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
3Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Dana-Farber Cancer Institute, Boston
5The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Newton, MA
6Division of Hematology, Dana-Farber Cancer Institute, Boston, MA
7Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA
8Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA
9Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
11The LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA

Jian Hou

Department of Hematology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Jian Hou1*, Weijun Fu, PhD2*, Soo-Mee Bang, MD, PhD3, Honghui Huang, PhD, MD1*, Kihyun Kim4*, Wei Li, MD5*, Gang An, MD, PhD6*, Je-Jung Lee, MD, PhD7, Zhen Cai8*, Jie Jin, MD8, Yafei Wang9*, CS Chim, MD, PhD, BMBS10, Paula Rodriguez-Otero11*, Meletios A. Dimopoulos, MD12, Tomoaki Fujisaki, MD13*, Jae Hoon Lee, MD, PhD14, Susan Wroblewski, PhD15*, Robin Carson, MD, BA15, Ming Qi, MD, PhD15, Jianping Wang16*, Yang Song17*, Bin Jia18*, Xue Yang18*, Wenyu Liu17*, Yunan Li19*, Renyi Zhang20* and Jianxiang Wang, MD6

1Department of Hematology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
2Shanghai Changzheng Hospital, Shanghai, China
3Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of (South)
4Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
5Department of Hematology at the Oncology Center, The First Hospital of Jilin University, Changchun, China
6Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7Department of Hematology-Oncology, Chonnam National University Medical School, Hwasun, Jeollanamdo, Korea, Republic of (South)
8The First Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, Zhejiang, China
9Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
10Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong
11Clinica Universidad de Navarra, IDISNA, Navarra, Spain
12National and Kapodistrian University of Athens, Athens, Greece
13Matsuyama Red Cross Hospital, Matsuyama, Japan
14Gachon University Gil Medical Center, Incheon, Korea, Republic of (South)
15Janssen Research & Development, LLC, Spring House, PA
16Janssen Research & Development, LLC, Raritan, NJ
17Janssen Research & Development, LLC, Beijing, China
18Janssen Research & Development, LLC, Shanghai, China
19Medical Affairs, Xian Janssen Pharmaceutical Ltd., Beijing, China
20Medical Affairs, Xian Janssen Pharmaceutical Ltd., Shanghai, China

Katja Weisel1*, Meletios A. Dimopoulos, MD2, Jesús San-Miguel, MD, PhD3, Agne Paner, MD4, Monika Engelhardt, MD5, Fiona Taylor6*, Jennifer Lord-Bessen, PhD7*, David Yao7*, Christine Yip8*, Mike Greenwood8*, Jackson Tang7* and Michele Cavo, MD, PhD9*

1Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
2National and Kapodistrian University of Athens School of Medicine, Athens, Greece
3Clínica Universidad de Navarra, Pamplona, Spain
4Rush University Medical Center, Chicago, IL
5University Medical Center Freiburg, Freiburg, Germany
6Adelphi Values, Boston, MA
7Bristol Myers Squibb, Princeton, NJ
8Adelphi Values, Bollington, United Kingdom
9IRCCS Azienda Ospedaliero Universitaria di Bologna, Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

Rose Turner, MBBS1, Hang Quach, FRACP, FRCPA2, Noemi Horvath, MB ChB FRACP FRCPA3, Ian H Kerridge, BA, BMed(Hons), MPhil(Cantab), FRACP, FRCPA4*, Flora Yuen, BBiomedSc5*, Edwin Sze-Hung Lee, MD, FRACP, FRCP, FRCPA, FRCPath6*, Edward S. Morris, BMBS, DM7, Anna Kalff, MBBS, FRACP, FRCPA, PhD8, Krystal Bergin, MBBS, FRACP, FRCPA8*, Shreerang Sridesai, MBBS, FRACP, FRCPA5*, Malgorzata Gorniak, BSc5*, Sridurga Mithraprabhu, PhD, MSc8*, Tiffany Khong, BSc, PhD8, John Reynolds, PhD8* and Andrew Spencer, MBBS, FRACP, FRCPA, DM8

1Alfred Health, Abbotsford, Vic, Australia
2St Vincent's Hospital - University of Melbourne, Melbourne, Australia
3Royal Adelaide Hospital, Adelaide, Australia
4Royal North Shore Hospital, Sydney, Australia
5Alfred Health, Melbourne, Australia
6Canberra Hospital, Canberra, Australia
7Townsville Cancer Centre, Townsville, QLD, Australia
8Alfred Health - Monash University, Melbourne, Australia

Pieter Sonneveld1, Sonja Zweegman2, Michele Cavo, MD, PhD3*, Kazem Nasserinejad, PhD4*, Annemiek Broyl1*, Rosella Troia5*, Ludek Pour, MD6*, Sandra Croockewit, MD7*, Paolo Corradini, MD8, Gerard M.J. Bos, MD, PhD9, Ka Lung Wu, MD10, Jolanda Droogendijk, MD11*, Monique C. Minnema, MD12 and Mario Boccadoro13

1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
2Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands
3Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy
4HOVON data center, Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
5hematology, University of Torino, torino, Italy
6Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
7Radboud University Medical Centre, Nijmegen, NLD
8Chair of Hematology, University of Milano Istituto Nazionale Tumori, Milano, Italy
9Division of Hematology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands
10Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
11hematology, tweesteden ziekenhuis, Tilburg, NLD
12Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
13Hematology Division, Department of Molecular Biotechnologies and Health Sciences, Cattedra Ematologia, Torino, Italy

Sueh-li Lim, MBBS, FRACP, FRCPA1,2, John Reynolds, PhD3,4,5,6*, Hang Quach, FRACP, FRCPA7,8, Anna Hutchinson, FRACP, FRCPA, BMedSci, MBBS9*, Ian H Kerridge, BA, BMed(Hons), MPhil(Cantab), FRACP, FRCPA10,11*, Jane Estell, B.Med FRACP FRCPA12, Wojt Janowski, BMed BSc, FRCPA, FRACP13, Craig Thomas Wallington-Beddoe, BSc, MBBS, MBiostat, PhD, FRACP, FRCPA14,15*, Anna Kalff, MBBS, FRACP, FRCPA, PhD1,2, Flora Yuen, BBiomedSc2* and Andrew Spencer, MBBS, FRACP, FRCPA, DM1,2

1Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia
2Malignant Haematology & Stem Cell Transplantation Services, Alfred Health, Melbourne, VIC, Australia
3Australasian Leukaemia and Lymphoma Group (ALLG), Melbourne, VIC, Australia
4Alfred Health - Monash University, Melbourne, Australia
5Biostatistics Consulting Platform, Alfred Health and Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, VIC, Australia
6The Alfred and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia
7St. Vincent’s Hospital, Melbourne, VIC, Australia
8University of Melbourne, Melbourne, VIC, Australia
9Department of Haematology, Royal Hobart Hospital, Hobart, TAS, Australia
10Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia
11University of Sydney, Sydney, NSW, Australia
12Haematology Department, Concord Cancer Centre, Concord Hospital, Concord, NSW, Australia
13Calvary Mater Newcastle, Waratah, AUS
14Department of Haematology, Flinders Medical Centre-College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Adelaide, Australia
15Flinders Medical Centre Flinders University, Adelaide, Australia

Robert Z. Orlowski1, Sosana Delimpasi, MD2*, Jan Straub, MD3*, Argiris Symeonidis, MD, PhD4, Luděk Pour, MD5*, Roman Hajek, MD, PhD6, Cyrille Touzeau, MD7*, Viralkumar K. Bhanderi, MD8*, Pawel J. Robak, MD PhD9*, Jesús G. Berdeja10, Jeffrey V. Matous, MD11, Lionel Karlin12*, Sonja Zweegman13, Sebastian Grosicki, MD, PhD14, Andrzej Pluta, MD15*, Suman Kambhampati, MD16*, Kaveri Suryanarayan, MD17*, Philip Twumasi-Ankrah17*, Ajeeta B. Dash, PhD17*, Richard Labotka, MD17 and Meletios A. Dimopoulos, MD18

1Departments of Lymphoma/Myeloma and Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Hematology and Bone Marrow Transplantation Unit, General Hospital Evangelismos, Athens, Greece
3Department of Internal Medicine - Hematology, University Hospital, Prague, Czech Republic
4Department of Hematology, University General Hospital of Patras, Patras, Greece
5Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
6University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
7University Hospital Hôtel Dieu, Nantes, France
8Florida Cancer Specialists, Tallahassee Cancer Center, Tallahassee, FL
9Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
10Sarah Cannon Research Institute, Nashville, TN
11Colorado Blood Cancer Institute, Sarah Cannon Research Institute, Denver, CO
12Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, Pierre-Benite, France
13Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
14Medical University of Silesia, Katowice, Poland
15Department of Hematological Oncology, Oncology Specialist Hospital, Brzozow, Poland
16Sarah Cannon Research Medical Center, Kansas City, MO
17Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
18National and Kapodistrian University of Athens, Athens, Greece

Hareth Nahi1*, Saad Z. Usmani, MD MBA FACP2, Maria-Victoria Mateos3, Niels W.C.J. van de Donk4, Philippe Moreau, MD, PhD5*, Albert Oriol6*, Torben Plesner, MD7, Nibedita Bandyopadhyay8*, Peter Hellemans9*, Brenda Tromp10, Ivo Nnane8*, Donna Zemlickis11*, Andrew Farnsworth12* and Ajai Chari, MD13*

1Karolinska University Hospital at Huddinge, Karolinska Institute, Stockholm, Sweden
2Levine Cancer Institute, New York, NY
3University Hospital of Salamanca/IBSAL/Cancer Research Center- IBMCC (USAL-CSIC), Salamanca, Spain
4Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, Netherlands
5Hematology, University Hospital Hôtel-Dieu, Nantes, France
6Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
7Vejle Hospital and University of Southern Denmark, Vejle, Denmark
8Janssen Research & Development, LLC, Raritan, NJ
9Janssen Research & Development, Beerse, Belgium
10Janssen Research & Development, Leiden, Netherlands
11Janssen Research & Development, LLC, Toronto, ON, Canada
12Janssen Research & Development, LLC, High Wycombe, United Kingdom
13Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY

Despina Fotiou, MD1*, Ioannis V Kostopoulos, PhD2*, Maria Krevvata, PhD3*, Maria Gavriatopoulou, MD1*, Ioannis Ntanasis-Stathopoulos, MD, MSc, PhD1*, Pantelis Roussakis, MSc2*, Chrysanthi Panteli2*, Panagiotis Malandrakis, MD1*, Magdalini Migkou, MD, PhD1*, Nikolaos Kanellias, MD1*, Evangelos Eleutherakis Papaiakovou, MD, MSc, PhD1*, Foteini Theodorakakou, MD1*, Evangelos Terpos, MD, PhD1, Ourania E. Tsitsilonis, MD, PhD2*, Meletios-Athanasios Dimopoulos, MD, PhD1 and Efstathios Kastritis, MD1*

1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2Department of Biology, National and Kapodistrian University of Athens, School of Science, Athens, Greece
3Janssen Research & Development, LLC, Spring House, PA

Irene Manrique1*, Richard Greil, MD2, Johannes Andel, MD3*, Siegfried Sormann4*, Bernd L. Hartmann, MD5*, Klaus Podar, MD, PhD6, Alexander Egle, MD2, Andreas Petzer, Univ. Prof., MD7, Niklas Zojer, MD8*, Eberhard Gunsilius, MD9*, Reinhard Ruckser, MD10, Boris Bozic, MD10*, Clemens A. Schmitt, MD11, Sigrid Machherndl-Spandl12*, Hermine Agis, MD13, Martin Schreder, MD8*, Song-Yau Wang, MD14*, Wolfgang Willenbacher, MD, PhD9,15, Maria-Theresa Krauth, MD13*, Christoph Tinchon, MD16*, Michael Fillitz, MD17*, Thomas Melchardt, Assoc. Prof., MD, PhD2*, Stefan Knop18*, Bruno Paiva, PhD1* and Heinz Ludwig, MD19

1Clinica Universidad de Navarra, Pamplona, Spain
2IIIrd Medical Department, Oncologic Center, Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT and Cancer Cluster Salzburg, Salzburg, Austria
3Department of Internal Medicine II, LKH Steyr, Steyr, Austria
4Department of Internal Medicine, University Clinic Graz, Graz, AUT
5Department of Internal Medicine II, LKH Rankweil, Rankweil, Austria
6University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria
7Department of Internal Medicine I, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria
8Department of Medicine I, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria
9Department of Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria
10Department of Medicine II, Clinic Donaustadt, Vienna, Austria
11Clinic for Internal Medicine 3, Kepler University Clinic Linz, Linz, Austria
12Department of Internal Medicine I, Ordensklinikum Linz Elisabethinen, Linz, Austria
13Department of Internal Medicine I, Divison of Hematology and Hemostaseology, Medical University Vienna, Vienna, Austria
14Department of Hematology, University Hospital of Leipzig, Leipzig, Germany
15Oncotyrol, Center for personalized Cancer Medicine, Innsbruck, Austria
16Department of Internal Medicine, LKH Hochsteiermark, Leoben, Austria
17Third Department of Internal Medicine, Hanusch Hospital, Vienna, Austria
18Division of Hematology and Medical Oncology, Department of Internal Medicine II, Wuerzburg University Medical Center, Wuerzburg, Germany
19Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria

Yifei Zhang, MD1, Amandeep Godara, MD2, Stacey Pan, MD3*, Denis Toskic, BS4*, Teresa Fogaren, NP5*, Douglas W. Sborov, MD, MSc6, Raymond Comenzo, MD7 and Ankit Kansagra, MD8

1Department of Medicine, Tufts Medical Center, Boston, MA
2Department of Hematology/Oncology, University of Utah, Salt Lake City, UT
3Tufts Medical, Boston, MA
4John C Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA
5Tufts Medical Center, Boston, MA
6Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
7Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA
8Blood and Marrow Transplant Program, University of Texas Southwestern Medical Center, Dallas, TX

Slavisa Ninkovic, MBBS1,2, Nicholas E. Murphy, FRCPA, MBBS, FRACP3,4, Hasib Sidiqi, MBBS5, Craig Thomas Wallington-Beddoe, BSc, MBBS, MBiostat, PhD, FRACP, FRCPA6*, Anish Puliyayil, MD. DM. FRACP.7*, Costas K. Yannakou, MBBS FRACP FRCPA8*, Wojt Janowski, BMed BSc, FRCPA, FRACP9, Flora Yuen, BBiomedSc10*, Andrew Spencer, MBBS, FRACP, FRCPA, DM11 and Hang Quach, FRACP, FRCPA12,13

1Faculty of Medicine, University of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, VIC, Australia
2Department of Haematology, St. Vincent's Hospital Melbourne, Melbourne, VIC, Australia
3University of Tasmania, Hobart, Australia
4Royal Hobart Hospital, Hobart, Australia
5Department of Haematology, Fiona Stanley Hospital, Perth, Australia
6Flinders Medical Centre Flinders University, Adelaide, Australia
7Border Medical Oncology and Haematology, Albury-Wodonga Cancer Centre, Albury, Australia
8Department of Molecular Oncology and Cancer Immunology, Epworth HealthCare, East Melbourne, VIC, Australia
9Calvary Mater Newcastle, Waratah, AUS
10Department of Clinical Haematology, Alfred Hospital, Melbourne, Australia
11Alfred Health - Monash University, Melbourne, Australia
12University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC, Australia
13St. Vincent’s Hospital, Melbourne, VIC, Australia

Evangelos Terpos, MD, PhD1, Efstathios Kastritis, MD1*, Evdoxia Hatjiharissi, MD2*, Eirini Katodritou, MD3*, Evangelos Eleutherakis Papaiakovou, MD, MSc, PhD1*, Evgenia Verrou, MD3*, Maria Gavriatopoulou, MD1*, Alexandros Leonidakis, PhD4*, Ioannis Ntanasis-Stathopoulos, MD1*, Sosana Delimpasi, MD5*, Marie-Christine Kyrtsonis, MD , PhD6, Maria Papaioannou2*, Argiris Symeonidis, MD, PhD7 and Meletios A. Dimopoulos, MD1

1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2First Department of Internal Medicine, Division of Hematology, AHEPA University Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece
3Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece
4Health Data Specialists S.A., Athens, Greece
5Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece
6First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
7Hematology Division, Department of Internal Medicine, University of Patras, Medical School, Patras, Greece

Ashutosh D. Wechalekar1,2,3,4*, John Silowsky, RN BSN5*, Eileen Daniel5*, Mark Harnett, MS6*, Michael Spector, BS7*, Susan B. Sobolov, PhD5*, Candida Cristina Quarta, MD8*, Michael R. Kurman, MD9, Mark Tulchinskiy, MD, MBA10*, Amit Bhattacharyya, PhD11* and Michaela Liedtke, MD12

1National Amyloidosis Centre, London, United Kingdom
2University College London Hospitals NHS Foundation Trust, London, United Kingdom
3University College London and the Royal Free London NHS Foundation Trust, Division of Medicine, Faculty of Medical Sciences, London, United Kingdom
4National Amyloidosis Centre, University College London, London, United Kingdom
5Caelum Biosciences, Bordentown, NJ
6Caelum Biosciences, Stow, MA
7Caelum Biosciences, Shamong, NJ
8Alexion, AstraZeneca Rare Disease, Boston, MA
9Michael Kurman Consulting, LLC, Upper Saddle River, NJ
10IQVIA Biotech, Morrisville, NC
11Alexion, AstraZeneca Rare Disease, Blue Bell, PA
12Division of Hematology, Department of Medicine, Stanford University, Stanford, CA

Alexander Lesokhin, MD1,2, Shinsuke Iida, MD, PhD3, Don Stevens, MD4, Afshin Eli Gabayan, MD5*, Wei Dong Ma6*, Sharon Sullivan, PhD7* and Marc-Steffen Raab8*

1Memorial Sloan Kettering Cancer Center, New York, NY
2Weill Cornell Medical College, New York, NY
3Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
4Norton Healthcare, Norton Cancer Institute, Louisville, KY
5Beverly Hills Cancer Center, Beverly Hills, CA
6Biostatistics, Pfizer Inc, New York, NY
7Pfizer Inc, Cambridge, MA
8Department of Hematology/Oncology, Heidelberg Myeloma Center, Heidelberg University Hospital, Heidelberg, Germany

Jesus Berdeja, MD1, Sikander Ailawadhi, MD2, Steven M. Horwitz, MD3, Jeffrey V. Matous, MD4, Neha Mehta-Shah, MD5, Thomas Martin, MD6, Eli Muchtar, MD7, Paul G. Richardson, MD8, Shambavi Richard9*, Manisha Bhutani, MD10, Andrew J. Yee, MD11, Michael R. Palmer, PhD12*, Cathleen Gorman, MSc.12*, Oliver Schoenborn-Kellenberger, MSc12*, Sanela Bilic, PharmD, MBA13*, Adam Crystal12*, Michelle Mahler, MD12 and Sagar Lonial, MD, FACP14

1Tennessee Oncology (Sarah Cannon Research Institute), Nashville, TN
2Division of hematology, Mayo Clinic, Jacksonville, FL
3Memorial Sloan Kettering Cancer Center, New York, NY
4Sarah Cannon Research Institute, Colorado Blood Cancer Institute, Denver, CO
5Washington University in St. Louis, Department of Medicine, Division of Hematology/Oncology, St. Louis, MO
6University of California San Francisco, San Francisco, CA
7Division of Hematology, Mayo Clinic Rochester, Saint Paul, MN
8Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
9Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
10Levine L. Cancer Institute, Charlotte, NC
11Massachusetts General Hospital Cancer Center, Boston, MA
12C4 Therapeutics, Watertown, MA
13Vanadro Consulting Inc, Watertown, MA
14Winship Cancer Institute, Emory University, Atlanta, GA

Parameswaran Hari1, Jesus G. Berdeja2, Valerio De Stefano3*, Francesca Gay, MD, PhD4*, Becky Hooper5*, Anja Haltner5*, Shaji K Kumar, MD6, Thomas Martin, MD7, Maria-Victoria Mateos8, Philippe Moreau, MD, PhD9*, Emily Rosta5*, Imtiaz A. Samjoo10*, Saad Z. Usmani, MD MBA FACP11, Katja Weisel12*, Carolyn C. Jackson13*, Yunsi Olyslager14*, Jordan M. Schecter13, Martin Vogel15*, Ashraf Garrett16*, Sam Lee16*, Tonia Nesheiwat16*, Lida Pacaud16*, Changwei Zhou16*, Satish Valluri, PhD15*, Luciano J. Costa, MD, PhD17 and Yi Lin6

1Medical College of Wisconsin, Milwaukee, WI
2Sarah Cannon Research Institute, Nashville, TN
3Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A Gemelli, IRCCS, Rome, Italy
4Division of Hematology, University of Torino, Torino, Italy
5EVERSANA, Sydney, NS, Canada
6Mayo Clinic, Rochester, MN
7UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
8Institute of Cancer Molecular and Cellular Biology, University Hospital of Salamanca, Salamanca, Spain
9Clinical Hematology, University Hospital Hotel-Dieu, Nantes, France
10EVERSANA, Burlington, ON, Canada
11Levine Cancer Institute, New York, NY
12University Medical Center Hamburg-Eppendorf, Hamburg, Germany
13Janssen R&D, Raritan, NJ
14Janssen Pharmaceutica NV, Beerse, Belgium
15Janssen Global Services, LLC., Raritan, NJ
16Legend Biotech USA, Piscataway, NJ
17University of Alabama at Birmingham, Birmingham, AL

Paula Rodríguez-Otero, MD, PhD1*, Veronica Gonzalez De La Calle, MD, PhD2*, Anna Sureda3, Felipe De Arriba, PhD4*, Marta Reinoso Segura5*, Paz Ribas6*, Ana Pilar Gonzalez, PhD7*, Yolanda Gonzalez-Montes8*, Albert Oriol9*, Joaquín Martínez-López10*, Marta Sonia Gonzalez, MD11*, Miguel T Hernández, MD, PhD12*, Maialen Sirvent13*, Joan Bladé Creixenti14, Juan Jose Lahuerta, MD, PhD15*, Jesús F. San-Miguel1 and Maria-Victoria Mateos16

1Clínica Universidad de Navarra, Pamplona, Spain
2Hospital Universitario de Salamanca Hematología. Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain
3Institut Català D'Oncologia, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain
4Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
5Instituto de Biomedicina de Sevilla (IBiS), UGC-Hematología, Hospital Universitario Virgen del Rocío/ CSIC/ CIBERONC, Universidad de Sevilla, Sevilla, Spain
6Hospital Dr. Peset, Valencia, Spain
7Hospital Central de Asturias, Oviedo, Spain
8Institut d’Oncologia Dr. Josep Trueta, Girona, Spain
9Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
10Hospital Universitario 12 de Octubre, Madrid, Spain
11Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
12Department of Hematology, Hospital Universitario de Canarias, La Laguna, Spain
13Hospital Universitario de Donostia, San Sebastián, Spain
14Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain
15Hospital Doce de Octubre, CIBERONC, Madrid, Spain
16Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain

Wee-Joo Chng, MBBS, PhD, FRCPath, FRCP1, Sagar Lonial, MD, FACP2, Gareth J. Morgan3*, Shinsuke Iida, MD, PhD4, Philippe Moreau, MD, PhD5*, Shaji K Kumar, MD6, Philip Twumasi-Ankrah7*, Arun Kumar7*, Ajeeta B. Dash, PhD7*, Alexander Vorog, MD8*, Xiaoquan Zhang, MD7*, Kaveri Suryanarayan, MD7*, Richard Labotka, MD7, Meletios A. Dimopoulos, MD9 and S. Vincent Rajkumar, MD6*

1Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
2Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University Medical School, Emory University, Atlanta, GA
3Perlmutter Cancer Center, NYU Langone Health, New York, NY
4Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
5Hematology Department, University Hospital Hotel Dieu, Nantes, France
6Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
7Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
8Takeda Development Center Americas, Inc., Lexington, MA
9National and Kapodistrian University of Athens, Athens, Greece

Paul G. Richardson, MD1,2, Ruben Niesvizky, MD3, Jay Yang, PhD4*, Neelu Yadav, PhD4*, Helen Hsu, MD4* and Christopher R. Flowers5

1Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
4Epizyme, Inc., Cambridge, MA
5Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX

Shaji K Kumar, MD1, Admasu Mamuye, MD, MSc2*, Kristina Dabovic, PharmD3*, Jingyuan Wang, PhD3*, Banmeet Anand, PhD4*, Amy Yuet, PhD4*, Bhagirathbhai Dholaria, MBBS5 and Vivek Roy, MD6

1Mayo Clinic, Rochester, MN
2Molecular Templates, Inc., New York, NY
3Molecular Templates, Inc., Jersey City, NJ
4Molecular Templates, Inc., Austin, TX
5Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
6Mayo Clinic, Jacksonville, FL

*signifies non-member of ASH